What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Anders Waage mainly investigates Internal medicine, Multiple myeloma, Endocrinology, Surgery and Tumor necrosis factor alpha.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Immunology.
In his study, Fatal outcome and Shock is strongly linked to Meningitis, which falls under the umbrella field of Immunology.
His work deals with themes such as Hematology, Cancer research and Bone marrow, which intersect with Multiple myeloma.
His Endocrinology research integrates issues from Cell culture and Receptor, Osteoclast.
His Surgery research includes themes of Lenalidomide and Oncology.
His most cited work include:
- The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. (1030 citations)
- Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. (1000 citations)
- Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma (905 citations)
What are the main themes of his work throughout his whole career to date?
Anders Waage focuses on Multiple myeloma, Internal medicine, Cancer research, Oncology and Immunology.
His studies deal with areas such as Molecular biology, Bone disease and Bone marrow as well as Multiple myeloma.
The study incorporates disciplines such as Endocrinology and Surgery in addition to Internal medicine.
His biological study spans a wide range of topics, including Cell culture, Growth factor, Cytokine and Hepatocyte growth factor.
His Oncology research is multidisciplinary, incorporating perspectives in Carfilzomib and Clinical trial.
His study in the fields of Interleukin 6 and Interleukin under the domain of Immunology overlaps with other disciplines such as Meningococcal disease.
He most often published in these fields:
- Multiple myeloma (54.62%)
- Internal medicine (49.23%)
- Cancer research (20.38%)
What were the highlights of his more recent work (between 2017-2021)?
- Multiple myeloma (54.62%)
- Internal medicine (49.23%)
- Oncology (18.08%)
In recent papers he was focusing on the following fields of study:
His main research concerns Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Cancer research.
His research on Multiple myeloma focuses in particular on Bortezomib.
Dexamethasone, Autologous stem-cell transplantation, Thalidomide, Maintenance therapy and Transplantation are the subjects of his Internal medicine studies.
His research in Oncology intersects with topics in Newly diagnosed, Carfilzomib, Staging system and Minimal residual disease.
His Cancer research research incorporates elements of Receptor, Myeloma cell, Treatment targets and Bone marrow.
His Immunology research incorporates themes from Osteoclast and Review article.
Between 2017 and 2021, his most popular works were:
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial (84 citations)
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study (58 citations)
- Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial (58 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His primary areas of study are Internal medicine, Multiple myeloma, Maintenance therapy, Transplantation and Regimen.
His works in Lenalidomide, Clinical endpoint, Autologous stem-cell transplantation and Progression-free survival are all subjects of inquiry into Internal medicine.
Multiple myeloma and Mechanism are two areas of study in which he engages in interdisciplinary research.
His Transplantation research is multidisciplinary, incorporating elements of Bortezomib, Ixazomib and Performance status.
His Regimen research is multidisciplinary, relying on both Clinical trial and Thalidomide.
Anders Waage interconnects Interleukin 6, Immunology, Bioinformatics and RANKL in the investigation of issues within Bone disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
